hope drug help patients alzheimer disease cases mount biogen said conducted new analysis consultation fda larger data set discontinued studies new analysis includes additional data available previous analysis showed studies futile"--that chance succeeding biogen said new data aducanumab pharmacologically clinically active reduced patients clinical decline based results survey called clinical dementia rating sum boxes cdr sb main goal studies devastating disease affects tens millions worldwide today announcement truly heartening fight alzheimer result groundbreaking research testament biogen steadfast determination follow science right thing patients michel vounatsos biogen chief executive said statement hopeful prospect offering patients therapy reduce clinical decline alzheimer disease